Connecticut is currently home to 1255 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
NCT03911700
Recruiting
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Open Midline Laparotomy
Register for Updates
Change 4 Better (C4B)
NCT06963931
Recruiting
The purpose of this research study is to determine the effectiveness of the Change4Better (C4B) mobile app at reducing the severity of problem gambling as compared to standard treatment as usual (TAU).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: CommuniCare, New Haven, Connecticut
Conditions: Problem Gambling
Register for Updates
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
NCT06671977
Recruiting
The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects. We expect that DMT will induce changes in neuroplasticity as indexed using electroencephalographic (EEG) measures and tasks in both depressed individuals and healthy volunteers, though to differe... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
05/01/2025
Locations: Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West Haven, Connecticut
Conditions: Major Depression Disorder, Depression
Register for Updates
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
NCT06014827
Recruiting
This phase II trial tests how well biologically guided radiation therapy (BgRT) and stereotactic body radiation therapy (SBRT) with osimertinib works for the treatment of EGFR positive non-small cell lung carcinoma that has spread from where it first started (primary site) to a limited number of anatomic sites (oligoprogressive). BgRT is radiation that uses specialized imaging to during treatment to target the active tumor and direct radiation to tumors in order to kill and shrink tumor cells. S... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673
Recruiting
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
05/01/2025
Locations: Yale-New Haven Hospital Saint Raphael Campus, New Haven, Connecticut
Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Register for Updates
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
NCT03509961
Recruiting
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regime... Read More
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
05/01/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
NCT03456843
Recruiting
This randomized phase II trial studies how well surgical removal of the prostate and antiandrogen therapy with or without docetaxel work in treating men with newly diagnosed prostate cancer that has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Antiandrogen therapy may lessen the amount of androgens made by the body. Drugs used in chemotherapy, such as docetaxel work in different ways to stop the growth of tumor cells, either by killing the cells, b... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Stage IV Prostate Adenocarcinoma AJCC v7
Register for Updates
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
NCT06525636
Recruiting
A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/30/2025
Locations: Yale Center for XLH/ Yale University School of Medicine, New Haven, Connecticut
Conditions: X-linked Hypophosphatemia
Register for Updates
Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
NCT06105931
Recruiting
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. Investigators aim to obtain reference data for individuals with T1D who do not have overweight obesity, to understand how close GLP-1 analogue obesity treatment in those with overweight/obesity brings physiologic markers of cardiometabolic risk to those with BMI in the normal range. Specifically, investigators will describe how driv... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/30/2025
Locations: Yale Pediatric Diabetes Research, New Haven, Connecticut
Conditions: type1diabetes, Obesity
Register for Updates
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05563220
Recruiting
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Yale School Of Medicine - Smilow Cancer Hospital - Breast Center, New Haven, Connecticut
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
The Periviable GOALS Decision Support Tool
NCT05264779
Recruiting
The Periviable GOALS (Getting Optimal Alignment around Life Support) decision support tool (DST) is meant to facilitate informed shared decision-making regarding neonatal resuscitation for families facing the threat of a periviable delivery (deliveries occurring between 22 0/7 - 25 6/7 weeks gestational age). It is designed for parents to review independent of their clinician, and is intended to supplement, not replace, clinician counseling. The focus of the DST is the provision of patient-cente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Pregnancy Preterm, Premature Birth, Pregnancy Complications, Obstetric Labor, Premature, Obstetric Labor Complications
Register for Updates
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML
NCT04256317
Recruiting
Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B). Phase 2 is a randomized, open-label, crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 is a randomized open-label crossover study comparing the fi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
Register for Updates